AMA. S. Mkrtchyan

A. S. Mkrtchyan

*This is an algorithmically generated author record based on publicly available information.

A. S. Mkrtchyan has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Population-based study of newly diagnosed multiple myeloma in Moscow: data from the Moscow City Cancer Registry (2022–2025)

    by E. N. Misyurina, Мисюрина Е. Н., E. N. Zotina, Зотина Е. Н., N. G. Chernova, Чернова Н. Г., G. A. Dudina, Дудина Г. А., T. N. Tolstykh, Толстых Т. Н., et al.

    Aim. To assess the registered incidence of multiple myeloma in Moscow, describe its age-, gender- and district-specific distribution, and provide a comprehensive clinical and biological characterization of adults with newly diagnosed multiple myeloma using the Moscow City Cancer Registry data for 2022–2025. Materials and methods. This retrospective population-based registry study included 1,899 adults with newly diagnosed multiple myeloma recorded in the Moscow City Cancer Registry in 2022–2025. Crude and age-standardized incidence rates were calculated. For each administrative district, the annual number of new cases was normalized to the corresponding adult population size and presented as incidence per 100,000 persons. Temporal trends were assessed using regression models accounting for district and population size. The diagnostic interval and completeness of staging were also analyzed. Results. The median age of patients was 68 [61; 74] years, and 55.1 % were women. Between 439 and 502 new cases were registered annually. No linear temporal trend was identified in the district-level analysis (p = 0.675). Mean annual crude district-specific rates ranged from 4.06 to 7.78 per 100,000 adults. The median diagnostic interval from the first outpatient visit to morphological verification was 19 [7; 54] days; the diagnosis was verified within ≤ 30 days in 61.2 % of cases. The proportion of patients assigned an mSMART 3.0 category increased from 36 % in 2022 to 70 % in 2025, while the availability of R2-ISS (Second Revision of the International Staging System) increased from 20 to 38 %. Conclusion. This population-based study provides the first comprehensive description of contemporary epidemiological, clinical and biological features of newly diagnosed multiple myeloma in Moscow using the Moscow City Cancer Registry. Age standardization demonstrated a higher registered incidence in men despite the predominance of women in the cohort. The results obtained show increasing implementation of molecular-genetic risk stratification and support the registry as an instrument for population monitoring and improvement of specialized oncohematological care.

  • Open Access

    Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma

    by M. A. Mingalimov, E. A. Baryak, A. V. Misyurin, L. A. Kesaeva, A. S. Mkrtchyan, E. N. Misyurina, M. A. Donskoy, T. N. Tolstykh, M. S. Orlova, T. S. Chudnova, et al.

    Background. Despite tremendous progress in understanding tumor biology, the R-CHOP protocol remains the standard of care for diffuse large B-cell lymphoma (DLBCL). To date, six genetic variants of DLBCL have been identified, the most unfavorable of which when using standard therapy are N1, MCD and BN2, which dictates the need to optimize the treatment of these DLBCL subtypes.Aim. To evaluate the efficacy and toxicity of Acala-R-CHOP regimen in induction therapy in patients with newly diagnosed DLBCL.Materials and methods. The study included 15 patients who received Acala-R-CHOP program as part of the first-line therapy. This antitumor regimen was used for verified genotypes N1, MCD and BN2. The median age was 64 (38–78) years. The incidence of genetic variants in the considered cohort of patients: MCD – 13 % (n = 2), N1 – 74 % (n = 11), BN2 – 13 % (n = 2).Results. Fifteen patients completed the therapy. The overall and complete metabolic response rates were 100 %. Toxicity was moderate, quite manageable and manifested mainly as myelosuppression.Conclusion. The efficacy of Acala-R-CHOP therapy in patients with MCD, N1, and BN2 DLBCL genotypes is high with a low toxicity profile. However, longer follow-up periods are needed to assess the long-term results in this unfavorable group of patients.

  • Open Access

    Molecular phenotype of diffuse large B-cell lymphoma as a basis for a personalized treatment approach of elderly patients

    by M. A. Mingalimov, E. A. Baryakh, A. V. Misyurin, L. A. Kesaeva, A. S. Mkrtchyan, E. N. Misyurina, M. A. Donskoy, T. N. Tolstykh, M. S. Orlova, T. S. Chudnova, et al.

    Background. The use of molecular genetic profiling in clinical practice and the registration of immunotargeted agents have undoubtedly led to the development of a personalized approach in oncohematology, with diffuse large B-cell lymphoma (DLBCL) being no exception. Elderly patients represent a complex group of patients with DLBCL, which leads to difficulties in treatment due to their comorbidity.Aim. To evaluate the efficacy, tolerability and safety of an individualized approach based on the mutational landscape in elderly patients with newly diagnosed DLBCL.Materials and methods. The clinical study included 10 elderly patients with newly diagnosed DLBCL. The median age was 68 (65–78) years. Eight patients were classified as being at high risk of early progression according to the international prognostic index. The frequency of genotypes in the considered cohort of elderly patients: MCD – 1 (10 %), N1 – 3 (30 %), BN2 – 1 (10 %), EZB – 2 (20 %), NOS – 3 (30 %).Results. Overall and complete metabolic response rates were 100 %. Clinically significant hematological toxicity depending on the number of cycles (n = 60): grade III–IV neutropenia in 5 cycles, grade III–IV thrombocytopenia in 2, grade III–IV anemia in 3. Non-hematological toxicity did not exceed grades I–II.Conclusion. High efficacy and low toxicity profile of a personalized approach in elderly patients with newly diagnosed DLBCL were demonstrated. The obtained preliminary results indicate the possibility of continuing the developed clinical study of elderly patients with DLBCL.

  • Open Access

    Personalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review

    by Marat Albertovich Mingalimov, E. A. Baryakh, T. N. Tolstykh, A. V. Misyurin, L. A. Kesaeva, A. S. Mkrtchyan, A. M. Kovrigina, E. N. Misyurina, M. S. Orlova, T. S. Chudnova, et al.

    The term “Diffuse Large B-Cell Lymphoma” (DLBCL) covers an extremely heterogeneous range of aggressive hematological tumors of lymphoid origin. The recommended standard first-line treatment R-CHOP is still the leading therapy for newly diagnosed DLBCL. However, the outcomes of the unified approach to chemotherapy disregarding a high clinical and molecular genetic heterogeneity of this variant of non-Hodgkin lymphoma are evaluated as unsatisfactory. This paper is the first in the Russian Federation to report the personal experience with the use of the combination of R-CHOP regimen as basic therapy and chemotherapeutic agent acalabrutinib, one of Bruton tyrosine kinase inhibitors, with respect to Sanger sequencing results.


  • Open Access

    Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)

    by M. A. Mingalimov, E. A. Baryakh, A. V. Misyurin, L. A. Kesaeva, A. S. Mkrtchyan, E. N. Misyurina, T. N. Tolstykh, M. S. Orlova, A. A. Akhmadeeva, T. S. Chudnova, et al.

    Background. Diffuse large B-cell lymphoma (DLBCL) is a potentially curable biologically heterogeneous lymphatic tumor. Standard R-CHOP therapy shows disappointing results, both immediate and longterm. To improve efficacy without additional toxicity, it is worth considering the possibility of using biologically oriented therapy.Aim. To evaluate the clinical efficacy and toxicity of the genotypedirected R-CHOP-X in patients with newly diagnosed DLBCL in real clinical practice.Materials and methods. A single-center prospective interventional clinical study included 30 patients with newly diagnosed DLBCL between September 2023 and September 2024. The median age was 60 (38–78) years. According to the international prognostic index, 23 (77 %) patients were classified as having a high risk of progression. Genotype incidence in the study cohort: MCD – 7 %, N1 – 20 %, BN2 – 7 %, EZB– 16 %, ST2 – 7 %, NOS – 43 %.Results. 30 patients received personalized genotype-directed therapy. Of these, 21 (70 %) patients completed treatment: the overall response rate was 100 % (complete metabolic response – 100 %). 9 (30 %) patients continue therapy: the overall response rate is 100 %. At 12 months, overall survival and progression-free survival were 100 % (95 % confidence interval 100 %). Hematological toxicity was assessed depending on the number of cycles (n = 144): grade III–I neutropenia was detected in 7 % of cycles, grade III–I anemia and grade III–I thrombocytopenia in 1.4 and 3.5 % of cycles, respectively. Non-hematological toxicity was generally grade ≤I–II.Conclusion. The results of this clinical trial are promising and provide preliminary evidence for the benefit of personalized genotype-directed antitumor therapy in newly diagnosed DLBCL. This therapeutic strategy demonstrates high clinical efficacy, particularly in the main target group – DLBCL with a high risk of progression with low toxicity. Further randomized studies are needed to confirm the effectiveness and implement the new approach in routine clinical practice.


  • Open Access

    Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma

    by A. A. Solodovnik, А. S. Mkrtchyan, V. A. Misyurin, L. A. Kesaeva, N. N. Kasatkina, O. M. Votyakova, O. Yu. Yakimovich, E. G. Medvedovskaya, A. S. Antipova, I. Z. Zavodnova, et al.

    Background . Multiple myeloma (MM) is a malignant lymphoproliferative B-cell disease characterization by clonal proliferation of plasma cells in the bone marrow and beyond its borders. Currently, a wide range of cytogenetic anomalies and molecular-biological parameters are studied as prognostic factors.Objective: a comparative study of the frequency, features and clinical significance of chromosomal abnormalities in MM by conventional cytogenetic and fluorescent in situ hybridization (FISH) methods.Materials and methods . 77 patients with MM, which admitted in N.N. Blokhin National Medical Research Center of Oncology, were included in the study from 2016 to 2017.Results . Chromosomal alterations were detected only in one case (1/77) by conventional cytogenetic method G-banding. However cytogenetic aberrations were revealed in 26 % of cases (20/77) using FISH. Deletions of different regions of chromosomes, indicating the possible presence of a hypodiploid clone or loss of some regions, were found in one patient in the second FISH analysis after 6 months. In the cohort of patients with chromosomal abnormalities (n = 20) a partial trisomy 11q, a deletion of the region q32 of the chromosome 14, a translocation t(4;14)(p16;q32) and IGHV gene rearrangement were determined in 30 % (6/20) as sole anomalies. Two or more cytogenetic aberrations were identified in the remaining 14 patients. Our study confirms that chromosomal abnormalities are more likely detected at later stages of MM (IA и IIA – 0 %, IIIA и IIIВ – 27 and 47 % respectively).Conclusion . FISH allows to detect chromosomal changes in tumor plasma cells regardless of the mitosis phase. In MM, it becomes particularly important in connection with low proliferative activity of plasma cells. Additionally, in the fourth of MM patients in the study submicroscopic chromosomal aberrations were discovered using FISH. The improvement of the probe panel and the widespread use of locus specific FISH don’t replace G-banding that allows to see damages of all chromosomes at once.


  • Open Access

    EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE

    by A. A. Solodovnik, H. S. Mkrtchyan, V. A. Misyurin, V. V. Tikhonova, Yu. P. Finashutina, N. N. Kasatkina, O. N. Solopova, O. M. Votyakova, O. Yu. Yakimovich, O. M. Volodina, et al.

    Objective: to study the prognostic significance of the expression of cancer-testis (CT) genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in patients with multiple myeloma (MM) and their influence on overall survival and relapse rate. To determine their effect on suсh clinical parameters as levels of lactate dehydrogenase, leucocytes, hemoglobin, calcium, albumen, creatinine, beta-2-microglobulin.Materials and methods. Real-time polymerase chain reaction was performed on complementary DNA obtained from bone marrow of 77 patients with MM. The statistical analysis was performed using the Statistica 10.0 software package. To estimate prognostic values of the CT gene expression data were analyzed by the Kaplan – Meier method.Results. The study was conducted to determine the level of expression of CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in a group of patients with MM. The group included primary and receiving cancer treatment in MM patients. According to the log-rank criterion expression of any of the CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 exerts a significant influence on overall survival and progression-free survival/relapse. It was also determined that providing expression of some CT genes, the levels of creatinine, calcium, beta-2-microglobulin were much higher to compare with patients without expression.